Patients who couldn’t tolerate GLP-1s or didn’t lose enough weight on them achieved meaningful weight loss with bariatric surgery, new research finds
Image content: This image is available to view online.
View image online (https://assets.clevelandclinic.org/transform/d1d9d4cd-230a-42be-888f-52fc6b9b18fc/Aminian-surgery)
Dr. Aminian in OR
A Cleveland Clinic study has found that patients with obesity who do not tolerate the weight-loss medications semaglutide or tirzepatide, or who do not lose enough weight with the medications, can achieve substantial weight loss after bariatric surgery. The research was recently published in Annals of Surgery.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
GLP-1 medications, like semaglutide and tirzepatide, have become widely used options for treating obesity. However, some patients have difficulty tolerating these medications, and others do not achieve the amount of weight loss they need. Previous research has found that roughly half of patients in real-world practice stop taking them within a year, making additional treatment options important.
“GLP-1 medications have transformed obesity care, but they don’t work for everyone,” says Ali Aminian, MD, director of Cleveland Clinic’s Bariatric and Metabolic Institute, and lead author of the study. “A growing number of patients and their doctors are asking: what’s the next step? Our findings show that bariatric surgery can be that next step.”
The new study found that bariatric surgery remained highly effective for patients who saw little to no benefit from GLP-1 medications. While patients lost about 2% of their body weight or less within two years of starting the medications, they lost considerably more after bariatric surgery, as detailed below. In several groups, weight loss was comparable to that of patients who had never used GLP-1 medications.
The observational study included 4,929 adults with obesity who underwent Roux-en-Y gastric bypass or sleeve gastrectomy at Cleveland Clinic hospitals in Ohio between 2018 and 2024. Researchers compared two-year total body weight loss outcomes among three groups: 4,661 patients who had not previously taken semaglutide or tirzepatide, 61 patients who stopped the medications because of intolerable side effects, and 207 patients who experienced inadequate weight loss while taking the medications. At the time of surgery, median body weight across the three groups ranged from approximately 273 to 287 pounds.
Advertisement
After accounting for age, sex, diabetes and other factors, total body weight loss two years after bariatric surgery varied by surgical approach. In each group, the lower figure reflects gastric sleeve and the higher figure reflects gastric bypass:
Both surgical approaches had low rates of complications.
“Most patients want to try GLP-1s as a less-invasive option first, but there are patients who prefer bariatric surgery,” explains Dr. Aminian. “Instead of staying on GLP-1 injections long term, they would rather have a two-hour procedure that can provide substantial, durable weight loss and health benefits. Patient’s preference is very important in decision-making.”
While semaglutide targets GLP-1 receptors and tirzepatide, a dual agonist, targets both GLP-1 and GIP receptors, bariatric surgery works through multiple additive mechanisms.
“Other hormones besides GLP-1 and GIP change in the body after surgery,” explains Dr. Aminian. “Surgery reduces the size of the stomach and reroutes the gastrointestinal tract. It substantially improves the patient’s insulin sensitivity, so it’s a great option for patients with insulin resistance and diabetes. Surgery also modifies the GI microbiome, the bile acid and the neurohormonal signaling.” In contrast to GLP-1 medications, which act on one or two specific pathways, bariatric surgery works through several at once.
Advertisement
According to the researchers, the study has some limitations. It was observational; the medication groups were relatively small, follow-up was limited to two years, and researchers could not confirm how consistently patients took their medications. The findings also do not mean that bariatric surgery is the appropriate next step for every patient who experiences medication intolerance or inadequate weight loss. Treatment decisions should be individualized based on a patient’s health, treatment history and preferences.
“Not losing weight with a GLP-1 medication doesn’t mean a patient won’t lose weight after bariatric surgery,” says Dr. Aminian. “Bariatric surgery can help patients achieve substantial weight loss.”
Dr. Aminian says that the research group hopes to do a clinical trial next.
“This was a two-year observational study,” he explains. “We need to follow these patients for a longer term — four or five years at least — and see what that longer-term data looks like. Obesity is a chronic disease, and it’s extremely hard to treat. The GLP-1 medications have been game-changers for how we treat the disease, but patients need lifelong support. Like other chronic diseases, we as clinicians need to have multiple tools in our toolbox, and our findings show that for patients who do not respond well to semaglutide or tirzepatide, bariatric surgery can be a very effective treatment.”
Advertisement
Advertisement
Patients may benefit from booster appointments, psychological support
Researchers explore how changes in the gut microbiome influence the brain's reward response to alcohol
Surgical intervention linked to increased lifespan and reduced complications
Retrospective study highlights psychosocial predictors of bariatric surgery outcomes
Comprehensive mental health screening may help prevent postsurgical risks
Consider each patient's unique disease progression and treatment goals when choosing a strategy
Sustained weight loss helps reduce IIH symptoms and medication dependence
Findings could help identify patients at risk for poor outcomes